Cargando…
Can Incobotulinumtoxin-A Treatment Improve Quality of Life Better Than Conventional Therapy in Spastic Muscle Post-Stroke Patients? Results from a Pilot Study from a Single Center
Post-stroke spasticity frequently occurs in patients with stroke, and there is a need for more quality-of-life assessments for different therapies. We evaluated for the first time in Romania the quality of life among patients with post-stroke spasticity, comparing two therapies over a 6-month period...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8303388/ https://www.ncbi.nlm.nih.gov/pubmed/34356168 http://dx.doi.org/10.3390/brainsci11070934 |
_version_ | 1783727074932948992 |
---|---|
author | Turcu-Stiolica, Adina Subtirelu, Mihaela-Simona Bumbea, Ana-Maria |
author_facet | Turcu-Stiolica, Adina Subtirelu, Mihaela-Simona Bumbea, Ana-Maria |
author_sort | Turcu-Stiolica, Adina |
collection | PubMed |
description | Post-stroke spasticity frequently occurs in patients with stroke, and there is a need for more quality-of-life assessments for different therapies. We evaluated for the first time in Romania the quality of life among patients with post-stroke spasticity, comparing two therapies over a 6-month period: botulinum toxin type A (BOT) with conventional therapy (CON). We also assessed the reduction of spasticity and functionality secondary to the increase in the mobility in upper limbs. This study was based on a prospective, randomized design, including subjects with post-stroke spasticity (N = 34; 34–80 years of age): in the CON arm, patients received therapy against muscle spasticity and physiotherapy, and, in the BOT arm, patients received incobotulinumtoxin-A and additionally conventional treatment, if required. Among 34 treated subjects in the two arms, the quality of life was significantly higher after BOT therapy (p < 0.001), represented by improvement in movement (p < 0.001), usual activities (p = 0.018), and distress (p < 0.001). Improvements in muscle tone (Ashworth Scale) over 6 months of treatment period were greater in the BOT arm (100%) than in the CON arm (11.8%). These preliminary results suggested that incobotulinumtoxin-A increased quality of life by improving movement, daily activities, mental health, and muscle tone more effectively than conventional therapy and could form a basis for future comparator studies. |
format | Online Article Text |
id | pubmed-8303388 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83033882021-07-25 Can Incobotulinumtoxin-A Treatment Improve Quality of Life Better Than Conventional Therapy in Spastic Muscle Post-Stroke Patients? Results from a Pilot Study from a Single Center Turcu-Stiolica, Adina Subtirelu, Mihaela-Simona Bumbea, Ana-Maria Brain Sci Article Post-stroke spasticity frequently occurs in patients with stroke, and there is a need for more quality-of-life assessments for different therapies. We evaluated for the first time in Romania the quality of life among patients with post-stroke spasticity, comparing two therapies over a 6-month period: botulinum toxin type A (BOT) with conventional therapy (CON). We also assessed the reduction of spasticity and functionality secondary to the increase in the mobility in upper limbs. This study was based on a prospective, randomized design, including subjects with post-stroke spasticity (N = 34; 34–80 years of age): in the CON arm, patients received therapy against muscle spasticity and physiotherapy, and, in the BOT arm, patients received incobotulinumtoxin-A and additionally conventional treatment, if required. Among 34 treated subjects in the two arms, the quality of life was significantly higher after BOT therapy (p < 0.001), represented by improvement in movement (p < 0.001), usual activities (p = 0.018), and distress (p < 0.001). Improvements in muscle tone (Ashworth Scale) over 6 months of treatment period were greater in the BOT arm (100%) than in the CON arm (11.8%). These preliminary results suggested that incobotulinumtoxin-A increased quality of life by improving movement, daily activities, mental health, and muscle tone more effectively than conventional therapy and could form a basis for future comparator studies. MDPI 2021-07-15 /pmc/articles/PMC8303388/ /pubmed/34356168 http://dx.doi.org/10.3390/brainsci11070934 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Turcu-Stiolica, Adina Subtirelu, Mihaela-Simona Bumbea, Ana-Maria Can Incobotulinumtoxin-A Treatment Improve Quality of Life Better Than Conventional Therapy in Spastic Muscle Post-Stroke Patients? Results from a Pilot Study from a Single Center |
title | Can Incobotulinumtoxin-A Treatment Improve Quality of Life Better Than Conventional Therapy in Spastic Muscle Post-Stroke Patients? Results from a Pilot Study from a Single Center |
title_full | Can Incobotulinumtoxin-A Treatment Improve Quality of Life Better Than Conventional Therapy in Spastic Muscle Post-Stroke Patients? Results from a Pilot Study from a Single Center |
title_fullStr | Can Incobotulinumtoxin-A Treatment Improve Quality of Life Better Than Conventional Therapy in Spastic Muscle Post-Stroke Patients? Results from a Pilot Study from a Single Center |
title_full_unstemmed | Can Incobotulinumtoxin-A Treatment Improve Quality of Life Better Than Conventional Therapy in Spastic Muscle Post-Stroke Patients? Results from a Pilot Study from a Single Center |
title_short | Can Incobotulinumtoxin-A Treatment Improve Quality of Life Better Than Conventional Therapy in Spastic Muscle Post-Stroke Patients? Results from a Pilot Study from a Single Center |
title_sort | can incobotulinumtoxin-a treatment improve quality of life better than conventional therapy in spastic muscle post-stroke patients? results from a pilot study from a single center |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8303388/ https://www.ncbi.nlm.nih.gov/pubmed/34356168 http://dx.doi.org/10.3390/brainsci11070934 |
work_keys_str_mv | AT turcustiolicaadina canincobotulinumtoxinatreatmentimprovequalityoflifebetterthanconventionaltherapyinspasticmusclepoststrokepatientsresultsfromapilotstudyfromasinglecenter AT subtirelumihaelasimona canincobotulinumtoxinatreatmentimprovequalityoflifebetterthanconventionaltherapyinspasticmusclepoststrokepatientsresultsfromapilotstudyfromasinglecenter AT bumbeaanamaria canincobotulinumtoxinatreatmentimprovequalityoflifebetterthanconventionaltherapyinspasticmusclepoststrokepatientsresultsfromapilotstudyfromasinglecenter |